PortalPublikationenMitraClip therapy in daily clinical practice: initial result...

MitraClip therapy in daily clinical practice: initial results from the German transcatheter mitral valve interventions (TRAMI) registry

Standard

MitraClip therapy in daily clinical practice: initial results from the German transcatheter mitral valve interventions (TRAMI) registry. / Baldus, Stephan; Schillinger, Wolfgang; Franzen, Olaf; Bekeredjian, Raffi; Sievert, Horst; Schofer, Joachim; Kuck, Karl-Heinz; Konorza, Thomas; Möllmann, Helge; Hehrlein, Christoph; Ouarrak, Taoufik; Senges, Jochen; Meinertz, Thomas; German Transcatheter Mitral Valve Intervention (TRAMI) investigators.

in: EUR J HEART FAIL, Jahrgang 14, Nr. 9, 09.2012, S. 1050-5.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Baldus, S, Schillinger, W, Franzen, O, Bekeredjian, R, Sievert, H, Schofer, J, Kuck, K-H, Konorza, T, Möllmann, H, Hehrlein, C, Ouarrak, T, Senges, J, Meinertz, T & German Transcatheter Mitral Valve Intervention (TRAMI) investigators 2012, 'MitraClip therapy in daily clinical practice: initial results from the German transcatheter mitral valve interventions (TRAMI) registry', EUR J HEART FAIL, Jg. 14, Nr. 9, S. 1050-5. https://doi.org/10.1093/eurjhf/hfs079

APA

Baldus, S., Schillinger, W., Franzen, O., Bekeredjian, R., Sievert, H., Schofer, J., Kuck, K-H., Konorza, T., Möllmann, H., Hehrlein, C., Ouarrak, T., Senges, J., Meinertz, T., & German Transcatheter Mitral Valve Intervention (TRAMI) investigators (2012). MitraClip therapy in daily clinical practice: initial results from the German transcatheter mitral valve interventions (TRAMI) registry. EUR J HEART FAIL, 14(9), 1050-5. https://doi.org/10.1093/eurjhf/hfs079

Vancouver

Baldus S, Schillinger W, Franzen O, Bekeredjian R, Sievert H, Schofer J et al. MitraClip therapy in daily clinical practice: initial results from the German transcatheter mitral valve interventions (TRAMI) registry. EUR J HEART FAIL. 2012 Sep;14(9):1050-5. https://doi.org/10.1093/eurjhf/hfs079

Bibtex

@article{4d06e09750104e5890f115f5678d5c72,
title = "MitraClip therapy in daily clinical practice: initial results from the German transcatheter mitral valve interventions (TRAMI) registry",
abstract = "AIMS: A substantial percentage of patients with mitral regurgitation (MR) in need of mitral valve repair are currently considered not suitable for conventional surgery. In Germany, the largest cohort of patients studied to date has been treated using a percutaneous, catheter-based approach. We report the acute outcomes of patients enrolled in the investigator-initiated German transcatheter mitral valve interventions (TRAMI) registry.METHODS AND RESULTS: Between January 2009 and August 2011, 486 patients [median age 75 (interquartile range 70-80) years; 200 women (41%)] were enrolled in the registry (309 retrospectively and 177 prospectively), with 481 patients (99%) having undergone percutaneous edge-to-edge therapy for MR using the MitraClip. At baseline, 93% of patients were in New York Heart Association (NYHA) functional class III or IV and 71% of patients had a left ventricular ejection fraction (LVEF) ≤50%. Two-thirds of patients presented with functional MR. Procedural success was achieved in 94% of patients, with grade III present in 93% of patients at baseline yet only 6% post-intervention. Retrospective patients were followed for a median of 183 days, prospective patients for a median of 44 days. The periprocedural complication rate was low, with only minor bleedings as the most significant event. In-hospital and post-discharge mortality was 2.5% and 12.5%, respectively.CONCLUSIONS: Data from the German TRAMI registry suggest that MitraClip therapy is a viable treatment option in daily clinical routine for high surgical risk patients with significant MR.",
keywords = "Aged, Aged, 80 and over, Cardiac Catheterization/methods, Cohort Studies, Female, Follow-Up Studies, Germany, Humans, Male, Mitral Valve, Mitral Valve Insufficiency/mortality, Patient Selection, Postoperative Complications, Prospective Studies, Registries, Retrospective Studies, Surgical Instruments, Treatment Outcome",
author = "Stephan Baldus and Wolfgang Schillinger and Olaf Franzen and Raffi Bekeredjian and Horst Sievert and Joachim Schofer and Karl-Heinz Kuck and Thomas Konorza and Helge M{\"o}llmann and Christoph Hehrlein and Taoufik Ouarrak and Jochen Senges and Thomas Meinertz and {German Transcatheter Mitral Valve Intervention (TRAMI) investigators}",
year = "2012",
month = sep,
doi = "10.1093/eurjhf/hfs079",
language = "English",
volume = "14",
pages = "1050--5",
journal = "EUR J HEART FAIL",
issn = "1388-9842",
publisher = "Oxford University Press",
number = "9",

}

RIS

TY - JOUR

T1 - MitraClip therapy in daily clinical practice: initial results from the German transcatheter mitral valve interventions (TRAMI) registry

AU - Baldus, Stephan

AU - Schillinger, Wolfgang

AU - Franzen, Olaf

AU - Bekeredjian, Raffi

AU - Sievert, Horst

AU - Schofer, Joachim

AU - Kuck, Karl-Heinz

AU - Konorza, Thomas

AU - Möllmann, Helge

AU - Hehrlein, Christoph

AU - Ouarrak, Taoufik

AU - Senges, Jochen

AU - Meinertz, Thomas

AU - German Transcatheter Mitral Valve Intervention (TRAMI) investigators

PY - 2012/9

Y1 - 2012/9

N2 - AIMS: A substantial percentage of patients with mitral regurgitation (MR) in need of mitral valve repair are currently considered not suitable for conventional surgery. In Germany, the largest cohort of patients studied to date has been treated using a percutaneous, catheter-based approach. We report the acute outcomes of patients enrolled in the investigator-initiated German transcatheter mitral valve interventions (TRAMI) registry.METHODS AND RESULTS: Between January 2009 and August 2011, 486 patients [median age 75 (interquartile range 70-80) years; 200 women (41%)] were enrolled in the registry (309 retrospectively and 177 prospectively), with 481 patients (99%) having undergone percutaneous edge-to-edge therapy for MR using the MitraClip. At baseline, 93% of patients were in New York Heart Association (NYHA) functional class III or IV and 71% of patients had a left ventricular ejection fraction (LVEF) ≤50%. Two-thirds of patients presented with functional MR. Procedural success was achieved in 94% of patients, with grade III present in 93% of patients at baseline yet only 6% post-intervention. Retrospective patients were followed for a median of 183 days, prospective patients for a median of 44 days. The periprocedural complication rate was low, with only minor bleedings as the most significant event. In-hospital and post-discharge mortality was 2.5% and 12.5%, respectively.CONCLUSIONS: Data from the German TRAMI registry suggest that MitraClip therapy is a viable treatment option in daily clinical routine for high surgical risk patients with significant MR.

AB - AIMS: A substantial percentage of patients with mitral regurgitation (MR) in need of mitral valve repair are currently considered not suitable for conventional surgery. In Germany, the largest cohort of patients studied to date has been treated using a percutaneous, catheter-based approach. We report the acute outcomes of patients enrolled in the investigator-initiated German transcatheter mitral valve interventions (TRAMI) registry.METHODS AND RESULTS: Between January 2009 and August 2011, 486 patients [median age 75 (interquartile range 70-80) years; 200 women (41%)] were enrolled in the registry (309 retrospectively and 177 prospectively), with 481 patients (99%) having undergone percutaneous edge-to-edge therapy for MR using the MitraClip. At baseline, 93% of patients were in New York Heart Association (NYHA) functional class III or IV and 71% of patients had a left ventricular ejection fraction (LVEF) ≤50%. Two-thirds of patients presented with functional MR. Procedural success was achieved in 94% of patients, with grade III present in 93% of patients at baseline yet only 6% post-intervention. Retrospective patients were followed for a median of 183 days, prospective patients for a median of 44 days. The periprocedural complication rate was low, with only minor bleedings as the most significant event. In-hospital and post-discharge mortality was 2.5% and 12.5%, respectively.CONCLUSIONS: Data from the German TRAMI registry suggest that MitraClip therapy is a viable treatment option in daily clinical routine for high surgical risk patients with significant MR.

KW - Aged

KW - Aged, 80 and over

KW - Cardiac Catheterization/methods

KW - Cohort Studies

KW - Female

KW - Follow-Up Studies

KW - Germany

KW - Humans

KW - Male

KW - Mitral Valve

KW - Mitral Valve Insufficiency/mortality

KW - Patient Selection

KW - Postoperative Complications

KW - Prospective Studies

KW - Registries

KW - Retrospective Studies

KW - Surgical Instruments

KW - Treatment Outcome

U2 - 10.1093/eurjhf/hfs079

DO - 10.1093/eurjhf/hfs079

M3 - SCORING: Journal article

C2 - 22685268

VL - 14

SP - 1050

EP - 1055

JO - EUR J HEART FAIL

JF - EUR J HEART FAIL

SN - 1388-9842

IS - 9

ER -